Clinical Trial Update: LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of LEO 27847 in patients with secondary hyperparathyroidism; the trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• LEO 27847

Snippet

Sponsor: LEO Pharma | Conditions: Secondary Hyperparathyroidism | Phase 1 | Status: COMPLETED